Moderna (NASDAQ:MRNA) Price Target Raised to $151.00

Moderna (NASDAQ:MRNA) had its price objective boosted by UBS Group from $143.00 to $151.00 in a research note released on Tuesday, Benzinga reports. UBS Group currently has a buy rating on the stock.

Several other equities research analysts have also recently weighed in on the company. Jefferies Financial Group reiterated a buy rating and issued a $125.00 price objective on shares of Moderna in a report on Tuesday, April 9th. Oppenheimer lifted their price target on shares of Moderna from $142.00 to $163.00 and gave the company an outperform rating in a report on Friday, May 3rd. William Blair restated a market perform rating on shares of Moderna in a report on Monday, April 1st. Royal Bank of Canada lifted their target price on shares of Moderna from $125.00 to $135.00 and gave the company an outperform rating in a research note on Friday, May 3rd. Finally, Needham & Company LLC reissued a hold rating on shares of Moderna in a research note on Thursday, May 2nd. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of Hold and a consensus price target of $126.89.

Moderna Stock Performance

NASDAQ:MRNA opened at $121.07 on Tuesday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.91 and a current ratio of 4.03. Moderna has a fifty-two week low of $62.55 and a fifty-two week high of $142.79. The business has a 50 day moving average price of $106.10 and a 200-day moving average price of $95.05. The firm has a market cap of $46.40 billion, a PE ratio of -7.73 and a beta of 1.57.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.59) by $0.52. The business had revenue of $167.00 million for the quarter, compared to analyst estimates of $93.26 million. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The company’s revenue was down 91.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.19 EPS. Equities research analysts predict that Moderna will post -7.47 earnings per share for the current year.

Insider Buying and Selling

In other Moderna news, insider Shannon Thyme Klinger sold 670 shares of Moderna stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $63,361.90. Following the completion of the transaction, the insider now directly owns 8,557 shares of the company’s stock, valued at $809,235.49. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Noubar Afeyan sold 15,000 shares of the stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $110.92, for a total transaction of $1,663,800.00. Following the sale, the director now directly owns 2,026,931 shares of the company’s stock, valued at $224,827,186.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Shannon Thyme Klinger sold 670 shares of Moderna stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $63,361.90. Following the completion of the sale, the insider now owns 8,557 shares of the company’s stock, valued at $809,235.49. The disclosure for this sale can be found here. Insiders have sold a total of 139,954 shares of company stock worth $14,822,576 in the last quarter. Corporate insiders own 15.20% of the company’s stock.

Institutional Trading of Moderna

A number of institutional investors have recently made changes to their positions in the stock. Ogorek Anthony Joseph NY ADV bought a new position in Moderna during the fourth quarter valued at approximately $27,000. Arlington Trust Co LLC boosted its stake in shares of Moderna by 4,833.3% in the 4th quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock worth $29,000 after buying an additional 290 shares during the last quarter. Westside Investment Management Inc. purchased a new position in shares of Moderna in the 1st quarter worth $32,000. Rise Advisors LLC grew its holdings in shares of Moderna by 953.3% in the first quarter. Rise Advisors LLC now owns 316 shares of the company’s stock worth $34,000 after acquiring an additional 286 shares during the period. Finally, UMB Bank n.a. increased its position in Moderna by 121.8% during the first quarter. UMB Bank n.a. now owns 366 shares of the company’s stock valued at $39,000 after acquiring an additional 201 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.